Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reportsReuters • 10/26/25
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026PRNewsWire • 10/13/25
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle SocietyPRNewsWire • 10/06/25
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 09/15/25
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common StockPRNewsWire • 09/11/25
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-ZotaSeeking Alpha • 09/11/25
Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga • 09/11/25
Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)Seeking Alpha • 09/10/25
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44PRNewsWire • 09/10/25
Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/08/25
Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/05/25
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?Zacks Investment Research • 08/25/25
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent HighlightsPRNewsWire • 08/07/25
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover DealInvestors Business Daily • 08/06/25
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory SubmissionPRNewsWire • 07/28/25
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 SkippingPRNewsWire • 07/23/25
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressPRNewsWire • 06/11/25
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD ParticipantsPRNewsWire • 06/09/25
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHDPRNewsWire • 06/09/25